ReviewPigment cell & melanoma research2013
Melanoma-associated leukoderma - immunology in black and white?
Review in Pigment cell & melanoma research, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 48 citations in OpenAlex.
- Halo Nevus as a Self-Limited Model of Melanocyte Autoimmunity: Bridging Vitiligo, Immune Resolution, and Tumor Immunology-A Narrative Review.Dermatopathology (Basel, Switzerland) · 2026Review
- [Melanocytic nevi in focus : Clinical interpretation, histopathological criteria, and practice-oriented management].Dermatologie (Heidelberg, Germany) · 2026Article
- Cancer Risk in Vitiligo: No Evidence of Increased Prevalence-A Systematic Review and Meta-analysis.Dermatology and therapy · 2025Article
- Perception of skin cancer risk and sun protective practices in individuals with vitiligo: a prospective international cross-sectional survey.Archives of dermatological research · 2024Article
- The many faces of autoimmune-mediated melanocyte destruction in melanoma.Frontiers in immunology · 2024Review
- Mendelian Randomization Analysis reveals Inverse Genetic Risks between Skin Cancers and Vitiligo.JID innovations : skin science from molecules to population health · 2023Article
- Macrophage Reprogramming with Anti-miR223-Loaded Artificial Protocells Enhances In Vivo Cancer Therapeutic Potential.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2022Article
- Current Challenges in Deciphering Sutton Nevi-Literature Review and Personal Experience.Journal of personalized medicine · 2021Review
- Article
- Eruptive Halo Naevi: A Possible Indicator of Malignant Disease in a Case Series of Post-Adolescent Patients.Acta dermato-venereologica · 2020Article
- Clinical and Pathological Relevance of Drug-induced Vitiligo in Patients Treated for Metastatic Melanoma with Anti-PD1 or BRAF/MEK Inhibitors.Acta dermato-venereologica · 2020Article
- HLA-A29 and Birdshot Uveitis: Further Down the Rabbit Hole.Frontiers in immunology · 2020Review
- Local depigmentation as a sign of local recurrence of a histologic complete regressed malignant melanoma.JAAD case reports · 2019Article
- Melanoma and Vitiligo: In Good Company.International journal of molecular sciences · 2019Review
- Pigmentation Disorders in the Elderly.Drugs & aging · 2019Review
- Onset of vitiligo following targeted therapy for BRAFDrugs in context · 2019Article
- HSP70iThe Journal of investigative dermatology · 2018Article
- Two reports of malignant melanoma arising within a new vitiligo-like depigmented patch.JAAD case reports · 2018Article
- Case of lymph node primary perivascular epithelioid cell tumor associated with leukoderma.The Journal of dermatology · 2017Article
- Elevated Levels of SOX10 in Serum from Vitiligo and Melanoma Patients, Analyzed by Proximity Ligation Assay.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Melanoma is an 'immunogenic tumor', often highly infiltrated with lymphocytes, which are capable of inducing regression of the primary tumor. The commonly observed phenomenon of regression suggests substantial cross-talk between immune cells and transformed melanocytes. An immune response to melanocyte differentiation antigens common to transformed and normal melanocytes manifests clinically at distant sites as melanoma-associated vitiligo or halo nevi. Despite similar antigenic targets, the pathogenesis and prognosis differ between the different melanoma-associated leukodermas. Understanding immunologic cross-talk between melanocytes and the immune system will aid the development of approaches to combat melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.